Herpes zóster en pacientes con enfermedades reumáticas inflamatorias crónicas autoinmunes: un llamado a la acción
Novedades y reflexiones para mejorar la vacunación en grupos vulnerables
Resumen
El herpes zóster (HZ) representa una complicación relevante en pacientes con enfermedades reumáticas inflamatorias crónicas autoinmunes (ERICA), especialmente en aquellos tratados con glucocorticoides, terapias biológicas e inhibidores de JAK. Este trabajo revisa la evidencia actual sobre el riesgo, impacto clínico y prevención del HZ en esta población vulnerable. Los estudios analizados muestran que la vacuna recombinante contra herpes zóster (RZV) es eficaz y segura, reduciendo significativamente la incidencia de HZ y sus complicaciones, incluso en pacientes inmunocomprometidos. Sin embargo, las tasas de vacunación continúan siendo bajas debido a barreras de acceso, falta de indicación médica y escasa percepción del riesgo. Se destaca la necesidad de fortalecer la educación médica, promover estrategias de vacunación y desarrollar recomendaciones prácticas que permitan optimizar la prevención del HZ y mejorar la calidad de vida de lospacientes con ERICA.Citas
Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019 Sep 19;5(2):e001041. doi: 10.1136/rmdopen-2019-001041.
Oleszko M, Zapolnik P, Kmiecik W, Czajka H. Herpes Zoster: Risk Factors for Occurrence, Complications, and Recurrence with a Focus on Immunocompromised Patients. Diseases. 2025, 13, 71. https://doi.org/10.3390/diseases13030071.
Chen J, Ho CY, Tu YK, Lin YC, Hsia Y, Shantakumar S. A systematic review and meta-analysis of herpes zoster risk in adults with immunocompromised conditions and autoimmune diseases in Asia-Pacific. Human Vaccines & Immunotherapeutics. 2025, 21(1). https://doi.org/10.1080/21645515.2025.2496048.
Comisión de Vacunas, SADI. Recomendaciones para la vacunación contra el herpes zoster 2023. Disponible en https://www.sadi.org.ar/publicaciones/1613-recomendaciones-2023-de-vacunacion-contra-el-herpes-zoster. Consultado el 07/01/2026
Bonvehí P, Citera G, Cosentino V, De la Vega MC, Larroudé MS, Nacinovich F, et al. Recomendaciones para la inmunización con vacuna recombinante para herpes zóster en pacientes con enfermedades reumáticas inflamatorias crónicas autoinmunes. Revista Argentina de Reumatología. Octubre-diciembre 2023, 34:Nº 3 (Suplemento Nº 2): 1-10.
Winthrop KL, Nash P, Yamaoka K, Mysler E, Khan N, Camp HS, et al. Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Ann Rheum Dis. 2022 Feb;81(2):206-213. doi: 10.1136/annrheumdis-2021-220822.
Rezahosseini O y cols. Temporal timing of herpes zoster events in relation to diagnosis of immunocompromising conditions. Nordsælands hospital, Hillerod, Denmark. Abstract P3640; ECCMID 2025, Viena, Austria.
Eiberg MF y cols. The risk of vascular events following herpes zoster: a matched cohort study. Copenhagen University Hospital, North Zealand, Hillerød (Denmark), Danish Cancer Society, Statens Serum Institut - (Denmark). Abstract P0229; ECCMID 2025, Viena, Austria.
Constenla D, Lonnet G, Aris E, Ramsanjay RK, Servotte N, Mwakingwe-Omari A, et al. Real-world effectiveness of the adjuvanted recombinant zoster vaccine in ≥50-year-old adults with autoimmune diseases. J Infect Dis. 2025:jiaf395. doi: 10.1093/infdis/jiaf395.
Rayens E, Sy L, Qian L, Wu J, Ackerson B, Luo Y, et al. Vaccine effectiveness and safety of recombinant Zoster Vaccine in Rheumatoid Arthritis Patients in Population Aged 50 years and older. Ravens E y cols. Kaiser permanente. Abstract Number: 0977. ACR Convergence 2024 November 14–19, Washington, DC.
Kluberg S, Mayer SE, Spence OM, Oraich D, Seifert H, Ali O, et al. Effectiveness and Safety of the Recombinant Zoster Vaccine in Patients ≥18 Years of Age with Systemic Lupus Erythematosus or Multiple Sclerosis. Abstract Number: 0844. ACR Convergence 2024 November 14–19, Washington, DC.
Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an OlderUS Population: A Cohort Study. Plos Med 2013;10(4)e10001420.
Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, et al. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y.
Winthrop KL, Klaff J, Penn SK, Liu Y, García C, Mysler E, et al. Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy. RMD Open. 2025;11:e005521. https://doi.org/10.1136/rmdopen-2025-005521.
Shih PC, Wang SI, Leong PY, Huo AP, Wei JCC. Recombinant Zoster Vaccine Reduces All-Cause Mortality, But Not Major Adverse Cardiovascular Events, in Patients With Immune-Mediated Inflammatory Diseases Receiving Janus Kinase Inhibitors: A Large-Scale Real-World Retrospective Cohort Study. J Med Virol. 2025 Mar;97(3):e70285. doi: 10.1002/jmv.70285.
Curtis JR, Conrad DM, Krueger WS, Gara AP, Winthropet KL. Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster. Arthritis Res Ther. 2025; 27, 108. https://doi.org/10.1186/s13075-025-03565-0.
Park JK, Kim M, Jung JI, Kim JY, Jeong H, Park JW, et al. Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024 Jun;6(6):e352-e360. doi: 10.1016/S2665-9913(24)00084-5.
Mayer SE, Kluberg SA, Spence O, Oraichi D, Seifert H, Ali O, et al. Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA. RMD Open. 2025 Aug 7;11(3):e005839. doi: 10.1136/rmdopen-2025-005839.
Bijl M, Westra J, Mancuso S, Bearzi P, Giacomelli R, Conti F. Should we vaccinate during an active rheumatic disease? Autoimmunity Reviews 2024; 23 (1):103426,ISSN 1568-9972, https://doi.org/10.1016/j.autrev.2023.103426.
Leung J, Anderson TC, Dooling K, Xie F, Curtis JR, et al. Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune-Mediated Inflammatory Diseases in the US. Arthritis Rheumatol. 2022 Nov;74(11):1833-1841. doi: 10.1002/art.42261.
Wesseley A. Seroconversion after application of a recombinant herpes zoster vaccine in VZV seronegative immunocompromised adults. Abstract P5061. ECCMID 2025, Viena, Austria.
Valdez Donelli F, Barbich T, Ezquer A, Bravo A, Lallopizzo C, Reyes Gómez C, et al. Estatus de vacunación contra influenza, neumococo y herpes zóster en pacientes con artritis reumatoide y espondiloartritis. Rev. argent. reumatolg. 2024, vol.35, n.3, pp.55-64. https://doi.org/10.47196/rar.v35i3.881.
Pier M, Wolbink G, Boekel L. Time to talk to adults with rheumatic diseases about herpes zoster vaccination. Lancet Rheumatol. 2024 Apr;6(4):e247-e251. doi: 10.1016/S2665-9913(24)00019-5.
Abreu C, Martins A, Branco E, Rocha R, Sarmento A, Magro F. Vaccines - beliefs and concerns: the voice of patients with inflammatory immunomediated diseases. Eur J Gastroenterol Hepatol. 2023 Aug 1;35(8):848-853. doi: 10.1097/MEG.0000000000002589.
Derechos de autor 2026 Los autores
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
